title: Cat-scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of the literature.
authors.affiliation: Department of Dermatology and Venereology, Centro Hospitalar de São João EPE, Porto, PortugalDepartment of Infectious Diseases, Centro Hospitalar de São João EPE, Porto, PortugalDepartment of Pharmacology and Therapeutics, Faculty of Medicine of University of Porto, Porto, Portugal.
authors.forename: Filipa
authors.initials: F
authors.lastname: Osório
authors.forename: Ana
authors.initials: A
authors.lastname: Pedrosa
authors.forename: Filomena
authors.initials: F
authors.lastname: Azevedo
authors.forename: Paulo
authors.initials: P
authors.lastname: Figueiredo
authors.forename: Sofia
authors.initials: S
authors.lastname: Magina
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001473:Bartonella / Q000302:isolation & purification*; D001474:Bartonella Infections / Q000150:complications* / Q000000981:diagnostic imaging; D002372:Cat-Scratch Disease / Q000000981:diagnostic imaging* / Q000382:microbiology*; D002415:Cats; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014463:Ultrasonography
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab